ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 140,31
0,40%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Oncolytics Biotech Inc (ONCY)

  7. Oncolytics Biotech Inc (ONCY) Actualités

ONCY

Oncolytics Biotech (ONCY)

Oncolytics Biotech Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ONCY
DateHeureSourceTitreSymboleSociété
07/03/202422h06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ONCYOncolytics Biotech Inc
26/09/202314h00PR Newswire (US)THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTSNASDAQ:ONCYOncolytics Biotech Inc
22/06/202315h23Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ONCYOncolytics Biotech Inc
03/03/202317h24Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:ONCYOncolytics Biotech Inc
09/12/202218h25TipRanksOncolytics Biotech (ONCY) Receives a Buy from Maxim GroupNASDAQ:ONCYOncolytics Biotech Inc
02/12/202218h25TipRanksMaxim Group Sticks to Its Buy Rating for Oncolytics Biotech (ONCY)NASDAQ:ONCYOncolytics Biotech Inc
23/11/202212h30TipRanksWall Street Analysts Are Bullish on Top Healthcare PicksNASDAQ:ONCYOncolytics Biotech Inc
22/11/202218h15TipRanksMaxim Group Reaffirms Their Buy Rating on Oncolytics Biotech (ONCY)NASDAQ:ONCYOncolytics Biotech Inc
18/08/202212h15TipRanksH.C. Wainwright Remains a Buy on Oncolytics Biotech (ONCY)NASDAQ:ONCYOncolytics Biotech Inc
15/07/202212h15TipRanksH.C. Wainwright Thinks Oncolytics Biotech’s Stock is Going to RecoverNASDAQ:ONCYOncolytics Biotech Inc
16/06/202222h22Edgar (US Regulatory)Amended Registration Statement for Securities of Certain Canadian Issuers Under the Securities Act of 1933 (f-10/a)NASDAQ:ONCYOncolytics Biotech Inc
10/06/202223h14Edgar (US Regulatory)Appointment of Agent for Service of Process and Undertaking (f-x)NASDAQ:ONCYOncolytics Biotech Inc
10/06/202212h01Edgar (US Regulatory)Registration Statement for Securities of Certain Canadian Issuers Under the Securities Act of 1933 (f-10)NASDAQ:ONCYOncolytics Biotech Inc
11/04/202212h15TipRanksAnalysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY), Stealth Biotherapeutics (MITO) and Genocea Biosciences (GNCA)NASDAQ:ONCYOncolytics Biotech Inc
07/03/202212h25TipRanksAnalysts’ Top Healthcare Picks: Check-Cap (CHEK), Axsome Therapeutics (AXSM)NASDAQ:ONCYOncolytics Biotech Inc
05/03/202217h05TipRanksLeede Jones Gable Thinks Oncolytics Biotech’s Stock is Going to RecoverNASDAQ:ONCYOncolytics Biotech Inc
10/01/202217h57PR Newswire (US)New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024NASDAQ:ONCYOncolytics Biotech Inc
05/03/202123h08Edgar (US Regulatory)Voluntary Supplemental Material Filed Pursuant to Section 11(a) of the Securities Act of 1933 by Foreign Issuers (suppl)NASDAQ:ONCYOncolytics Biotech Inc
26/08/202016h15Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:ONCYOncolytics Biotech Inc
16/06/202012h00Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ONCYOncolytics Biotech Inc
12/12/201813h00GlobeNewswire Inc.Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor ...NASDAQ:ONCYOncolytics Biotech Inc
03/12/201813h00GlobeNewswire Inc.Oncolytics Biotech® Announces Increased PD-L1 Expression When Combining Pelareorep with a Proteasome Inhibitor in Poster Pr...NASDAQ:ONCYOncolytics Biotech Inc
29/11/201813h00GlobeNewswire Inc.Oncolytics Biotech® Announces Appointment of Rita Laeufle, M.D., as Chief Medical OfficerNASDAQ:ONCYOncolytics Biotech Inc
26/11/201814h00GlobeNewswire Inc.Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda® in Advanced Pancrea...NASDAQ:ONCYOncolytics Biotech Inc
13/11/201813h00GlobeNewswire Inc.Oncolytics Biotech® Announces Attendance of Upcoming ConferencesNASDAQ:ONCYOncolytics Biotech Inc
12/11/201813h00GlobeNewswire Inc.Oncolytics Biotech® Reports 2018 Third Quarter Financial Results and Provides Corporate UpdateNASDAQ:ONCYOncolytics Biotech Inc
09/11/201813h00GlobeNewswire Inc.Oncolytics Biotech® Announces Presentation at the Society for Immunotherapy of Cancer 2018 Annual Meeting Showcasing Upregul...NASDAQ:ONCYOncolytics Biotech Inc
05/11/201813h00GlobeNewswire Inc.Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Corporate HighlightsNASDAQ:ONCYOncolytics Biotech Inc
01/11/201812h00GlobeNewswire Inc.Oncolytics Biotech® Announces Abstract for ASH Annual Meeting & Exposition Demonstrating Pelareorep Increases PD-L1 Expressi...NASDAQ:ONCYOncolytics Biotech Inc
25/10/201802h25GlobeNewswire Inc.Oncolytics Biotech® Establishes New At-The-Market FacilityNASDAQ:ONCYOncolytics Biotech Inc
 Showing the most relevant articles for your search:NASDAQ:ONCY

Dernières Valeurs Consultées

NYSE
MRK
Merck
NYSE
MCD
McDonalds
EU
CS
Axa
EU
RNO
Renault
SPI
SP500
S&P 500
COIN
ETHUSD
Ethereum
NASDAQ
MSFT
Microsoft
EU
AF
Air FranceKLM
EU
AI
Air Liquide
USI
USTECH100
US Tech 100
NASDAQ
GOOGL
Alphabet
EU
BN
Danone
EU
SGO
Cie de SaintGobain
EU
VK
Vallourec
EU
PX4
SBF 120
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés